AirSculpt Technologies, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This filing reports annual results; it does not provide a clear standalone fourth-quarter financial summary. AirSculpt operates body-contouring centers and recognizes revenue from procedures performed by affiliated professional associations, which it consolidates. Its services are generally paid for upfront by patients.
Key financial and operating metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $195.9 million | $168.8 million |
| Operating income (loss) | $9.5 million | ($4.5 million) |
| Net income (loss) | ($4.5 million) | ($14.7 million) |
| Operating cash flow | $24.0 million | $24.4 million |
| Capital expenditures | $9.9 million | $12.9 million |
| Adjusted EBITDA, non-GAAP | $43.2 million; 22.1% margin | $38.9 million; 23.0% margin |
- Revenue grew 16.1%. Cases performed rose 14.3% to 14,932, while revenue per case increased 1.5% to $13,121. The company added five centers, ending the year with 27 centers and 57 procedure rooms.
- Cost of service was $74.0 million, or 37.8% of revenue, versus 37.2% in 2022. Gross profit was approximately $121.9 million, a 62.2% margin. GAAP operating margin was 4.8%; net margin was negative 2.3%.
- Same-center cases declined 1.4%, while same-center revenue per case increased 1.5%. Thus, overall growth was supported by new centers despite lower same-center case volume.
- Cash and cash equivalents were $10.3 million at year-end; $5.0 million was available under the revolving facility. Working capital was negative $4.4 million.
- Year-end term-loan principal was $72.9 million, down from $85.0 million after a voluntary $10.0 million prepayment. The loan carried a 7.85% variable rate and matures in 2027. Contractual debt principal, interest and operating-lease payments totaled $130.7 million, including $14.1 million due within one year.
Changes, outlook and notable items
- Revenue and operating income improved year over year, but the company still reported a GAAP net loss. Income-tax expense was $7.5 million despite $3.0 million of pretax income; the reported effective tax rate was 249.4%, primarily affected by nondeductible executive compensation and state taxes.
- Adjusted EBITDA increased, but its margin fell from 23.0% to 22.1%. This non-GAAP measure excludes, among other items, equity compensation, interest and taxes.
- Management said operating cash flows and available revolver capacity should fund working capital, debt payments and planned capital needs for at least the next 12 months. It targets opening three to four centers annually and expects ongoing investment in marketing and expansion. The filing gives no specific financial guidance.
- Advertising costs were $25.9 million; total selling expenses were $36.8 million, and customer acquisition cost was approximately $2,465 per customer. About 47% of cases involved third-party patient financing; AirSculpt says it does not bear default risk under those arrangements.
- Material risks include discretionary consumer demand and economic conditions; competition from weight-loss drugs and other treatments; recruiting surgeons; execution and returns on new centers; dependence on a single handpiece supplier; variable-rate debt; healthcare regulation, including corporate-practice-of-medicine and fee-splitting rules; medical-liability exposure; and privacy and cybersecurity risks.
- Management reported effective disclosure controls and internal control over financial reporting at year-end. The auditor gave an unqualified opinion on the financial statements but was not engaged to opine on internal-control effectiveness. The company reported no current legal proceedings expected to have a material adverse effect, while noting outcomes cannot be assured.
Investor verification priorities
- Review same-center case declines and the contribution, ramp-up and profitability of newly opened centers.
- Assess whether cash generation can support expansion, leases and debt service, particularly with negative working capital and variable-rate borrowing.
- Reconcile GAAP losses with Adjusted EBITDA and review the size and treatment of equity compensation and restructuring costs.
- Track patient demand, financing availability and competitive effects from weight-loss drugs, along with marketing efficiency and acquisition costs.
- Monitor supplier concentration, medical-liability claims, regulatory compliance and cybersecurity safeguards.